Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02259582 · ClinicalTrials.gov registry record · Phase 2
A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by OncoMed Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
NCT02259582 is a Phase 2 study that has completed, run by OncoMed Pharmaceuticals. The registered enrollment target is 82 participants.
The verdict
NCT02259582, a Phase 2 study, has completed, sponsored by OncoMed Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
Study Summary
A randomized, double-blind, 3-arm (1:1:1) study in subjects with first-line Stage IV non-squamous NSCLC. The purpose is to test the efficacy and safety of demcizumab, when given in combination with carboplatin and pemetrexed compared to placebo. The administration of carboplatin and pemetrexed is a standard treatment for patients with non-squamous non-small cell lung cancer.
Interventions
- DRUG Carboplatin
- DRUG Pemetrexed
- DRUG demcizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2015-02 |
| Est. Completion | 2017-04-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02259582
The ClinicalTrials.gov registry entry for NCT02259582 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OncoMed Pharmaceuticals, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT02259582 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02259582 about?
NCT02259582 is a clinical study titled "A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer". A randomized, double-blind, 3-arm (1:1:1) study in subjects with first-line Stage IV non-squamous NSCLC. The purpose is to test the efficacy and safety of demcizumab, when given in combination with carboplatin and pemetrexed compared to placebo. The administration of carboplatin and pemetrexed is a ...
What is the current status of trial NCT02259582?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2015-02. Estimated completion is 2017-04-07.
What interventions are being tested in trial NCT02259582?
The interventions under investigation include: Carboplatin (DRUG), Pemetrexed (DRUG), demcizumab (DRUG).
Who is sponsoring clinical trial NCT02259582?
This trial is sponsored by OncoMed Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.